CoChat

Exenatide once weekly improved 24‐hour glucose control and reduced glycaemic variability in metformin‐treated participants with type 2 diabetes: a randomized, placebo‐controlled trial

Open access
Frías, Juan P., Nakhle, Samer, Ruggles, James A., Zhuplatov, Sergey, Klein, Eric, Zhou, Rong, Strange, Poul · 2017 · Diabetes, Obesity and Metabolism
Cited by 28

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Aim: To assess the effects of once‐weekly exenatide on 24‐hour glucose control and variability. Materials and methods: This double‐blind, placebo‐controlled trial randomized metformin‐treated adults with type 2 diabetes to once‐weekly exenatide 2.0 mg or placebo. Continuous glucose monitoring ( CGM ) was performed at baseline and weeks 4 and 10. The primary outcome was change in CGM ‐measured 24‐hour mean glucose level. Results: In the once‐weekly exenatide (n = 60) and placebo (n = 56) groups (modified intention‐to‐treat population), the baseline glycated haemoglobin ( HbA1c ) concentrations were 8.2% and 8.0%, respectively, and the fasting plasma glucose ( FPG ) concentration was 9.86 and 9.32 mmol/ L , respectively. Once‐weekly exenatide significantly (p < 0.001) reduced 24‐hour mean glucose level versus placebo (week 4, −1.44 vs −0.29 mmol/ L ; week 10, −1.71 vs −0.17 mmol/ L ), with consistent control throughout the week. Once‐weekly exenatide significantly reduced FPG and 2‐hour postprandial glucose ( PPG ) levels versus placebo at week 4 ( FPG , −1.65 vs −0.11 mmol/ L ; PPG , −1.79 vs −0.11 mmol/ L ) and week 10 ( FPG , −2.32 vs −0.28 mmol/ L ; PPG , −2.46 vs −0.33 mmol/ L ). At week 10, once‐weekly exenatide reduced the mean amplitude of glucose excursions ( MAGE ; −0.84 vs 0.16 mmol/ L ) and standard deviation (s.d.) of mean glucose (−0.35 vs 0.04 mmol/ L ). By week 10, once‐weekly exenatide‐treated participants spent more time in euglycaemia (once‐weekly exenatide, 77% vs placebo, 58%), less time in hyperglycaemia (22% vs 42%), and a similar time in hypoglycaemia (0.7% vs 0.3%). Common adverse events were injection‐site nodule (once‐weekly exenatide, 10.0% vs placebo, 0.0%), urinary tract infection (6.7% vs 8.9%) and nausea (6.7% vs 0.0%). Conclusions: In metformin‐treated participants with type 2 diabetes, once‐weekly exenatide significantly improved daily glucose control and reduced glycaemic variability at weeks 4 and 10, as shown by reductions in 24‐hour glucose, FPG and PPG levels, MAGE and s.d., and increased time spent in euglycaemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12763

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

Metadata

Authors
Frías, J. P., Nakhle, S., Ruggles, J. A., Zhuplatov, S., Klein, E., Zhou, R., & Strange, P.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2016-09-21
Volume
19
Issue
1
Pages
40-48
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2507708274
Cited by
28
References
6
FWCI
2.60
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.